Ryuji Hayashi

4.2k total citations · 1 hit paper
113 papers, 3.2k citations indexed

About

Ryuji Hayashi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ryuji Hayashi has authored 113 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 41 papers in Oncology, 34 papers in Pulmonary and Respiratory Medicine and 24 papers in Molecular Biology. Recurrent topics in Ryuji Hayashi's work include Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (15 papers) and Neuroendocrine Tumor Research Advances (10 papers). Ryuji Hayashi is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Lung Cancer Research Studies (15 papers) and Neuroendocrine Tumor Research Advances (10 papers). Ryuji Hayashi collaborates with scholars based in Japan, United States and United Kingdom. Ryuji Hayashi's co-authors include Richard P. Hsung, Andrew G. Lohse, Kyle A. DeKorver, Hongyan Li, Zhenjie Lu, Yu Zhang, Gregory R. Cook, Kazuhiro Ito, Ian M. Adcock and Shoko Matsui and has published in prestigious journals such as Chemical Reviews, Journal of the American Chemical Society and Journal of Biological Chemistry.

In The Last Decade

Ryuji Hayashi

100 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ynamides: A Modern Functional Group for the New Millennium

2010 813 citations Ryuji Hayashi et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ryuji Hayashi Japan	28	1.4k	669	417	328	290	113	3.2k
Bhaskar C. Das United States	32	798 0.6×	1.4k 2.2×	322 0.8×	101 0.3×	341 1.2×	111	3.4k
Hao Xie United States	31	1.4k 1.0×	810 1.2×	630 1.5×	372 1.1×	416 1.4×	143	3.7k
Juha Saarnio Finland	31	444 0.3×	1.6k 2.3×	491 1.2×	715 2.2×	240 0.8×	105	3.4k
Jun Yu China	32	391 0.3×	1.2k 1.7×	625 1.5×	375 1.1×	131 0.5×	139	3.0k
Yuri Miura Japan	29	267 0.2×	1.1k 1.6×	141 0.3×	156 0.5×	109 0.4×	99	2.4k
Weiming Kang China	23	326 0.2×	497 0.7×	264 0.6×	520 1.6×	74 0.3×	127	1.9k
Francesca Cirillo Italy	29	241 0.2×	895 1.3×	513 1.2×	174 0.5×	123 0.4×	68	2.2k
Alexandros Charalabopoulos Greece	29	782 0.5×	717 1.1×	983 2.4×	364 1.1×	159 0.5×	172	3.2k
Jose Luis García‐Giménez Spain	34	227 0.2×	1.7k 2.5×	535 1.3×	156 0.5×	282 1.0×	115	3.3k
Hyunseung Lee South Korea	31	431 0.3×	1.1k 1.6×	372 0.9×	160 0.5×	245 0.8×	107	2.5k

Countries citing papers authored by Ryuji Hayashi

Since Specialization

Citations

This map shows the geographic impact of Ryuji Hayashi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ryuji Hayashi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ryuji Hayashi more than expected).

Fields of papers citing papers by Ryuji Hayashi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ryuji Hayashi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ryuji Hayashi. The network helps show where Ryuji Hayashi may publish in the future.

Co-authorship network of co-authors of Ryuji Hayashi

This figure shows the co-authorship network connecting the top 25 collaborators of Ryuji Hayashi. A scholar is included among the top collaborators of Ryuji Hayashi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ryuji Hayashi. Ryuji Hayashi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nguyen, Khanh Cong, Yue Zhou, Satoru Yokoyama, et al.. (2025). Allosteric SHP2 inhibitors suppress lung cancer cell migration by inhibiting non-canonical activation of EphA2 via the ERK-RSK signaling pathway. Scientific Reports. 15(1). 36926–36926.

Kajiura, Shinya, Akihiro Yoshida, Akira Ueda, et al.. (2024). Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia. Journal of Palliative Medicine. 27(7). 922–925.

Hayashi, Ryuji, Junichi Matsubara, Masahiro Yoshioka, et al.. (2024). Molecularly matched therapies identified by comprehensive genomic profiling before the first-line setting to provide alternative treatment outcomes in patients with solid tumors: 1-year follow-up of the prospective FIRST-Dx study.. Journal of Clinical Oncology. 42(16_suppl). 3137–3137.

Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2023). Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer. Scientific Reports. 13(1). 10807–10807. 10 indexed citations

Kajiura, Shinya, et al.. (2023). Discharge to home from a palliative care unit: impact on survival and factors associated with home death after the discharge: a cohort study. BMC Palliative Care. 22(1). 191–191. 2 indexed citations

He, Ka, et al.. (2023). Calorie Restriction Impairs Anti-Tumor Immune Responses in an Immunogenic Preclinical Cancer Model. Nutrients. 15(16). 3638–3638. 2 indexed citations

Nishino, Yoshikazu, T Takiguchi, Shintaro Kanda, et al.. (2023). Multi-institutional survey of antiemetic therapy in lung cancer patients treated with carboplatin in Hokushin region. BMC Pulmonary Medicine. 23(1). 228–228. 2 indexed citations

Kajiura, Shinya, et al.. (2023). Multifocal fatty liver nodules mimicking a metastatic disease: A case report. SHILAP Revista de lepidopterología. 19(3). 850–854.

Koizumi, Tomonobu, Yoshikazu Nishino, T Takiguchi, et al.. (2022). Epidemiological and Therapeutic Analyses in Lung Cancer Patients Over 80 Years Old in the Hokushin Region: A Retrospective Hospital Administrative Database Study. Clinical Lung Cancer. 24(2). 145–152. 2 indexed citations

10.

Nishino, Yoshikazu, Kazuo Sakashita, Azusa Tanimoto, et al.. (2021). Cancer among children, adolescents and young adults in the Hokushin region, Japan, between 2010 and 2015. Japanese Journal of Clinical Oncology. 52(1). 86–95. 2 indexed citations

11.

Takata, Naoki, Seisuke Okazawa, Kenta Kambara, et al.. (2020). Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer. Tumori Journal. 107(6). 536–541. 2 indexed citations

12.

Inomata, Minehiko, Naoki Takata, Seisuke Okazawa, et al.. (2020). Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy. Diagnostics. 10(12). 1006–1006. 13 indexed citations

13.

Morita, Tatsuya, et al.. (2018). Impact of a Six-Year Project to Enhance the Awareness of Community-Based Palliative Care on the Place of Death. Journal of Palliative Medicine. 21(10). 1494–1498. 11 indexed citations

14.

Inomata, Minehiko, Seisuke Okazawa, Kenta Kambara, et al.. (2018). Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy. Pathology & Oncology Research. 26(1). 327–333. 18 indexed citations

15.

Inomata, Minehiko, Hiroaki Tanaka, Seisuke Okazawa, et al.. (2017). Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression. Oncology and Therapy. 5(2). 181–185. 1 indexed citations

16.

Hayashi, Ryuji, Seisuke Okazawa, Kenta Kambara, et al.. (2017). SIRT1 and FOXO1 mRNA expression in PBMC correlates to physical activity in COPD patients. International Journal of COPD. Volume 12. 3237–3244. 19 indexed citations

17.

Lee, Kang‐Yun, Kazuhiro Ito, Ryuji Hayashi, et al.. (2006). NF-κB and Activator Protein 1 Response Elements and the Role of Histone Modifications in IL-1β-Induced TGF-β1 Gene Transcription. The Journal of Immunology. 176(1). 603–615. 144 indexed citations

18.

Maruyama, Muneharu, Toru Yamada, Ryuji Hayashi, et al.. (2005). Doxorubicin induces expression of multidrug resistance-associated protein 1 in human small cell lung cancer cell lines by the c-jun N-terminal kinase pathway. International Journal of Cancer. 117(1). 21–31. 38 indexed citations

19.

Taniguchi, Ataru, Yoshikatsu Nakai, Mitsuo Fukushima, et al.. (2002). Ultrasonographically assessed carotid atherosclerosis in Japanese type 2 diabetic patients: Role of nonesterified fatty acids. Metabolism. 51(5). 539–543. 17 indexed citations

20.

Hayashi, Ryuji, Naohiro Yamashita, Shoko Matsui, et al.. (2000). Bradykinin stimulates IL-6 and IL-8 production by human lung fibroblasts through ERK- and p38 MAPK-dependent mechanisms. European Respiratory Journal. 16(3). 452–452. 83 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact